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Introduction
Doxorubicin is a glycosidic anthracycline anticancer drug, and it 
was first isolated from Streptomyces peucetius in 1960s. Although 
it has a strong anticancer effect, doxorubicin is also known to cause 
cardiotoxicity that leads to arrhythmia and congestive heart fail-
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ure.1) A variety of studies have been tried to discover the mecha-
nisms involved in doxorubicin-induced cardiotoxicity, and apoptosis 
induced by reactive oxygen species has been inferred as the most 
important mechanism to explain doxorubicin-induced cardiotoxic-
ity.2)3) Therefore, understanding the doxorubicin-induced apoptosis 
signaling process and investigation of the possible candidate mol-
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ecules which have an anti-apoptotic effect against doxorubicin in-
jury are crucial.
Survivin is the smallest member of the inhibitor of apoptosis (IAP) 
gene family and it is known as a bifunctional protein that acts as 
an apoptosis suppressor, and is an important factor in regulating 
proper cell division.4) Although its mechanism is not clearly under-
stood, survivin is considered to be a key factor in regulating cell sur-
vival and suppression of apoptosis. Survivin is overexpressed dur-
ing development and in most human cancer tissues. It has been 
reported that survivin was able to suppress caspase-3 and -7 even 
though the in vitro binding experiment failed to show this result. It 
is also known that survivin interacts with Smac, which is the inhibi-
tor of other IAPs.5) Such accumulated evidence suggests that sur-
vivin has the potential to regulate apoptosis and cell survival. Sur-
vivin is also detectable in terminally differentiated tissues such as 
the myocardium.6) However, the molecular function of survivin in 
cardiac myocytes has not been clearly determined.
Since the main role of survivin is considered to be the suppres-
sion of caspases and apoptosis, survivin may be one of appropriate 
targets for the doxorubicin-induced cardiac myocyte apoptosis sig-
nal cascade. Apoptosis of cardiac myocytes leading to loss of con-
tractile units has been implicated in the development of cardiomy-
opathy.7) The microtubule localization of survivin and the enhance-
ment of microtubule structure stability with the overexpression of 
survivin are important evidence to show that survivin might be one 
of the targets for doxorubicin injury because those cytoskeletal pro-
teins are essential in heart contraction.8) Furthermore, it was re-
ported that the inhibition of survivin resulted in similar biochemical 
interactions as the treatment of doxorubicin9) and heart failure was 
induced in a survivin knock-out mouse model.10)
In the present study, a recombinant survivin that was fused to the 
protein transduction domain (PTD) derived from HIV-TAT protein11) 
was delivered into H9c2 cardiomyocytes. A viral carrier was used 
because the transfection efficacy of delivery to cardiac myocytes 
with a non-viral carrier is extremely poor. And then, we evaluated 
the anti-apoptotic effect of PTD-mediated transduction of the re-
combinant survivin against doxorubicin injury with the apoptosis-
related signals.
Materials and Methods
Construction and protein purification of TAT-survivin
The survivin fragment was inserted into the BamHI and XhoI sites 
of the pHis/TAT vector12) for TAT-survivin fusion protein expression. 
E. coli BL21 transformed with recombinant plasmid was expressed at 
37°C in Lunia-Bertani broth. The bacterial pellet was harvested and 
resuspended in buffer (8 M urea, 100 mM NaCl, and 20 mM Hepes, 
pH 8.0). The clarified lysate was loaded onto a Ni-iminodiacetic acid 
affinity column (Macherey-Nagel, Germany). TAT-survivin protein 
was eluted with imidazole in buffer. The proteins were loaded onto a 
PD-10 desalting column in order to exchange the buffer to phos-
phate buffer saline (PBS). 
Cell culture and protein transduction into cells 
The rat heart-derived myoblast cell line, H9c2 cardiac myocytes, 
were obtained from the American Type Culture Collection (USA). 
H9c2 cardiac myocytes were cultured in Dulbecco’s modified Eagle’s 
Medium (DMEM) supplement with 10% fetal bovine serum (FBS) 
and 1% penicillin streptomycin (Gibco, USA) at 37°C in humidified 
atmosphere of 5% CO2. All experiments were performed using cells 
between 10 to 25 passage numbers. H9c2 cardiac myocytes were 
incubated for 24 hours in 100 mm culture plate and changed to 
0.5% FBS DMEM for 24 hours starvation. After starvation, they were 
treated with 1 μM of doxorubicin (Tocris, USA) for 24 hours. For the 
transduction of TAT-survivin, cells were treated with 1 μM of TAT-
survivin for 1 hour prior to doxorubicin.
Subcellular fractionation 
Cell pellets were separated into cytoplasmic, nucleic, membrane 
and mitochondrial fractions using the Mitochondria Isolation Kit 
(Qiagen, Germany) according to the manufacturer’s instructions. Af-
ter washing, cells were suspended in lysis buffer to disrupt the plas-
ma membrane without solubilizing it and to aid in the isolation of cy-
tosolic proteins. Plasma membranes and compartmentalized or-
ganelles, such as nuclei, mitochondria, and the endoplasmic reticu-
lum, remained intact and were pelleted by centrifugation at 1000× 
g for 10 minutes. The resulting pellet was resuspended in disruption 
buffer, repeatedly passed through a narrow-gauge needle (26 or 21 
gauge), and re-centrifuged to pellet nuclei, cell debris, and unbroken 
cells at 1000×g for 10 minutes. The supernatant which contained 
mitochondria and the microsomal fraction was recentrifuged to 
pellet mitochondria at 6000×g for 10 minutes. After removal of the 
supernatant, mitochondria and nuclei were dissolved using a lysis 
buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis as outlined below.
Reverse transcription-polymerase chain reaction
Total ribonucleic acid (RNA) isolated from cells using QIAzol-Re-
agent (Qiagen, Germany) was reverse transcribed using Omniscript 
Reverse Transcriptase (Qiagen, Germany). The cDNAs was amplified 
using Taq deoxyribonucleic acid (DNA) polymerase (Cosmo Genet-
ech, Korea). The following primer sequences were used: Bcl-2 
primers 5’-GACGCGAAGTGCTATTGGT-3’ and 5’-TCAGGCTGGAAG 
GAGAAGAT-3’, GAPDH primers 5’-AATGCATCCTGCACCACCAACT 
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GC-3’ and 5’-GGAGGCCATGTAGGCCATGAGGTC-3’. Polymerase 
chain reaction (PCR) products were separated by electrophoresis in 
a 1% agarose gel containing Gel-red (Biotium, USA).
Immunoblot analysis
Cells were solubilized in a cell lysis buffer (Cell signaling, USA) and 
centrifuged at 13000 rpm for 1 hour at 4°C. The proteins samples 
were separated by an SDS-polyacrylamide gel and transferred to 
polyvinylidene difluoride membranes. After blocking in TBS-tween 
20 (TBS-T, 0.1% tween 20) containing 5% non-fat dry milk, the 
membrane was treated with the appropriate primary antibodies: 
survivin, cleaved caspase-3, phospho-cyclic adenosine monophos-
phate response elements-binding protein (CREB) (Ser133), CREB, 
phospho-p38MAPK (Thr183/Tyr185), p38MAPK (Cell Signaling, 
USA), BAX, Bcl-2 (Abcam, USA), Smac, β-actin, GAPDH, Lamin B, 
His-tag (SantaCruz Biotechnology, USA), cytochrome C (Clontech, 
USA), followed by incubation with the appropriate horseradish per-
oxidase-conjugated secondary antibodies. The antigen-antibody bands 
were detected using enhanced chemiluminescence reagent kit (Milli-
pore, USA) and quantified by densitometry.
Cell viability, caspase-3 activity and terminal 
deoxynucleotidyltransferase-mediated dUTP nick 
end-labeling assay
Cell viability was measured by the classical 2-(4,5-dimethyltri-
azol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Amresco, 
USA). H9c2 cardiac myocytes were incubated for 24 hours in 24-
well plate and changed to 0.5% FBS DMEM media for 20 hours 
starvation. Cells were pretreated with TAT-survivin 1 μM for 1 hour, 
and then treated with 1 µM of doxorubicin for 24 hours. Cell viabili-
ty was determined by MTT solution which was added to each well 
to a final concentration of 0.5 mg/mL and was incubated at 37°C 
for 1-2 hours. The formazan crystals were dissolved by adding di-
methylsulfoxide and absorbance was measured at the 570 nm with 
a spectrophotometer. 
The activity of caspase-3 in the cells was determined spectro-
photometrically with an ApoalertTMCPP32/caspase-3 assay kit (BD 
Biosciences, USA) by measuring the release of the chromophore, p-
nitroanilide (pNA), following hydrolysis of DEVD-pNA. Terminal de-
oxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) 
analysis was performed with a commercially available kit according 
to the manufacturer’s instructions (Intergen, USA).
 
Immunofluorescence microscopy
The cells were incubated on Lab-Tek chamber slides (Nalgene 
Nunc, USA) and treated with 1 μM wt-survivin or TAT-survivin. Fol-
lowing incubation for 1 hour, the cells were washed twice with PBS 
and then fixed with 3% paraformaldehyde for 10 minutes at room 
temperature and washed with PBS. The cells were permeabilized in 
0.5% Triton X-100 buffer (0.5% Triton X-100, 20 mM Hepes-KOH, 
pH 7.9, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose) in PBS for 10 
minutes and washed with PBS. They were blocked with PBS contain-
ing 0.3% goat serum and 5% bovine serum albumin for 1 hour at 
room temperature and then incubated for 1 hour with the His-tag 
antibody. The cells were washed with PBS once and incubated with 
rhodamine Red-X, goat anti-rabbit IgG (R6394, dilution 1 : 500; In-
vitrogen) as secondary antibody for 1 hour in a dark room. After wa-
shing, the cells were mounted with ProLongantifade reagent con-
taining 4’-6-diamidino-2-phenylindole. The immunoreactive sig-
nals were visualized by confocal laser scanning microscope LSM700 
(Carl Zeiss, Germany).
Fig. 1. Effect of doxorubicin on cell viability and survivin level in H9c2 cardiac myocytes. A: H9c2 cardiac myocytes were treated with various concentra-
tions of doxorubicin for 24 hours. Cell viability was assessed by MTT assay. The results present the means of three independent experiments. *p<0.05 com-
pared to control. B: H9c2 cardiac myocytes were treated with doxorubicin for 24 hours. Equal amounts of protein were separated by SDS-PAGE gel, and 
immunoblot analysis was performed using anti-survivin antibody. C: cells were incubated with 1 µM of doxorubicin. At the indicated times, survivin levels 
were determined by immunoblot analysis. SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
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Statistical methods
Data are expressed as means±SE statistical comparisons were 
performed by one-way analysis of variance and Student’s t-test. Dif-
ferences were considered significant at p<0.05.
Results
Doxorubicin decreases survivin level in H9c2 cardiac myocytes
When the cells were treated with various amounts of doxorubicin 
for 24 hours, cell viability gradually decreased to about 60% with up 
to 1 µM of doxorubicin (p<0.05) (Fig. 1A). The treatment of 5 µM of 
doxorubicin did not further decrease cell viability compared to that 
of 1 µM of doxorubicin. We next studied whether the expression 
level of survivin was altered by doxorubicin treatment. The expres-
sion of survivin was dramatically suppressed when the cells were 
treated with no more than 1 µM of doxorubicin (Fig. 1B). Therefore, 
we fixed the amount of doxorubicin to treat H9c2 cardiac myocytes 
as 1 µM for further experiments. And Fig. 1C shows the time-depen-
dent decrease of survivin following treatment with 1 µM of doxo-
rubicin. 
TAT-survivin fusion protein is efficiently delivered into H9c2 
cardiac myocytes
TAT-survivin protein was transduced into H9c2 cardiac myocytes 
efficiently in a concentration-dependent manner (data not shown). 
TAT-survivin (1 µM) was detected by immunoblot using anti-His-tag 
antibody (Fig. 2A). And the immunofluorescence microscopy image 
using primary anti-His-tag antibody and Rhodamine-conjugated 
secondary antibody also showed efficient transduction of TAT-sur-
vivin protein (Fig. 2B). The red and blue staining in the image repre-
sent the transduced TAT-survivin proteins and nuclei, respectively.
TAT-survivin protein protects H9c2 cardiac myocytes from 
doxorubicin-induced apoptosis
We next examined whether intracellular delivery of TAT-survivin 
protected H9c2 cardiac myocytes against doxorubicin-induced in-
jury. We observed a significant protective effect of the TAT-survivin 
protein against doxorubicin-induced cell death. As shown in Fig. 
3A, caspase-3 activity was increased more than 3-fold after doxo-
rubicin treatment. However, TAT-survivin transduction significantly 
decreased caspase-3 activity (p<0.05) (Fig. 3B). Also, TUNEL assay 
demonstrated the anti-apoptotic effect of TAT-survivin against 
doxorubicin-induced injury (p<0.05) (Fig. 3C).
Fig. 2. Intracelluar delivery of recombinant TAT-survivin protein. A: H9c2 
cardiac myocytes were treated with TAT-survivin protein for 1 hour. Immu-
noblot analysis was performed with anti-His-tag antibody. Normalized 
densitometric intensities of levels for transduced protein are shown as av-
erage fold changes. B: immunofluorescence microscopy analysis of H9c2 
cardiac myocytes treated with 1 µM wt-survivin or TAT-survivin fusion 
proteins. After 1 hour, the cells were incubated with primary anti-His-tag 
antibody and Rhodamine-conjugated secondary antibody.
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TAT-survivin transduction leads to recovery of expression 
of Bcl-2 but not Bax
Apoptotic signals were evaluated to define the effect of TAT-sur-
vivin transduction on doxorubicin-induced apoptosis. To get inform-
ation about the relationship between doxorubicin-induced apoptosis 
and apoptosis related signals, we first measured the changes of Bax 
and Bcl-2 by immunoblot analysis. As shown in Fig. 4A, Bax protein 
level was increased following doxorubicin treatment, whereas Bcl-2 
level was decreased. Treatment of TAT-survivin protein led to signifi-
cant recovery of Bcl-2 in doxorubicin stimulus. However, there was 
no change observed in Bax protein with TAT-survivin treatment un-
der the same conditions (Fig. 4A). Reverse transcription-PCR showed 
that the expression of Bcl-2 was down-regulated by doxorubicin 
treatment, which was significantly recovered by TAT-survivin trans-
duction (Fig. 4B). Next, we investigated the subcellular localization 
of a proapoptotic mitochondrial protein Smac and cytochrome C, 
endogenous inhibitors of IAPs, released from mitochondria during 
apoptosis. TAT-survivin protein also inhibited the release of Smac 
and cytochrome C from the mitochondria to the cytoplasm induced 
by doxorubicin treatment (Fig. 4C). The activation of CREB, which is 
Fig. 4. Effects of TAT-survivin on Bcl-2 expression in H9c2 cardiac myocytes. H9c2 cardiac myocytes were treated with 1 µM of TAT-survivin for 1 hour 
and then subjected to doxorubicin treatment for 24 hours. A: whole cell lysates were immunoblotted with anti-Bax or anti-Bcl-2 antibody. B: total RNA 
was purified from cells and subjected to RT-PCR using primers specific for Bcl-2. C: mitochondrial and cytoplasm fractions were prepared, and equal 
amounts of protein were separated by SDS-PAGE gel. The release of Smac and cytochrome C from mitochondria was detected using an anti-Smac and an-
ti-cytochrome C antibody. D: equal amounts of nuclear protein were separated by SDS-PAGE gel, and immunoblot analysis was performed using anti-
phospho-CREB or anti-CREB antibody. E: whole cell lysates were immunoblotted with anti-phospho-p38 or anti-p38 antibody. SDS-PAGE: sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, RNA: ribonucleic acid, CREB: cyclic adenosine monophosphate response elements-binding protein.
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known as a transcription factor of Bcl-2, was quantified in both 
whole cell lysate and nuclear protein. As shown in Fig. 4D, doxorubi-
cin prevented the nuclear translocation of CREB. However, a signifi-
cant restoration of CREB nuclear translocation was observed in the 
treatment of TAT-survivin protein (Fig. 4D). The phosphorylated form 
of p38 MAP kinase, which is known as the upstream signal regula-
tor of doxorubicin-induced apoptosis was decreased with TAT-sur-
vivin treatment (Fig. 4E).
Discussion
Doxorubicin is one of the most widely used anticancer drugs, but 
its cumulative and dose-dependent cardiotoxicity has been a major 
concern in clinical practice for decades. This doxorubicin-induced 
cardiotoxicity leads to cardiac myocyte death, progressive cardio-
myopathy, and congestive heart failure.1) Although intensive inves-
tigations on doxorubicin-induced cardiotoxicity have been per-
formed over the decades, the underlying mechanisms responsible 
for doxorubicin-induced cardiotoxicity have not been completely 
elucidated. A rapidly expanding body of evidence supports the no-
tion that cardiac myocyte death by apoptosis and necrosis is a pri-
mary mechanism of doxorubicin-induced cardiotoxicity.1-3)
In the present study, survivin, known as a strong anti-apoptosis 
factor, was successfully delivered into H9c2 cardiac myocytes us-
ing the PTD system, leading to a significant cytoprotective effect 
against doxorubicin-induced apoptosis. The transduction of TAT-
survivin significantly reduced cell death and caspase activity. The 
induction of Bcl-2, which is known as an anti-apoptosis factor, also 
manifested the anti-apoptotic effect of TAT-survivin. Both protein 
level and mRNA level of Bcl-2 were increased by TAT-survivin trans-
duction. We also demonstrated that the activation of CREB, which is 
the transcription factor of Bcl-2, was also increased by TAT-survivin. 
CREB has been established as a cellular transcription factor which 
binds to a specific DNA site called cyclic adenosine monophosphate 
response element (CRE) that regulates the transcription of several 
proteins including the expression of the IAP family,13)14) leading to 
an upregulation of Bcl-2 expression that is related to anti-apoptosis. 
Other reports showed that activation of CREB also increased the 
expression level of the IAP family.15) The present findings, with pro-
tein delivery of TAT-survivin, suggest that Bcl-2 may be at least in 
part involved in the cytoprotection mechanism with TAT-survivin 
against doxorubicin insult, and that recovery of Bcl-2 level may be 
attributed to the CREB reactivation by TAT-survivin treatment. Fur-
thermore, TAT-survivin transduction recovered its translocation of 
Smac into mitochondria from the cytoplasm. Smac is a mitochon-
drial protein that promotes apoptosis by inhibiting IAPs. Survivin is 
considered to inhibit Smac by binding to it in the cytosol,5) but the 
transduction of survivin also suppressed the release of Smac from 
the mitochondria in our study. Although the interaction between 
Smac and survivin in the mitochondria is not proven, this result 
can be explained by the activation of Bcl-2. It is reported that Bcl-
2 attenuated the release of Smac from the mitochondria.16) We also 
observed that doxorubicin-induced cytochrome C release from mi-
tochondria is inhibited by TAT-survivin protein transduction. Besides 
its interaction with Smac as already reported, survivin may also bind 
to other upstream proteins of Bcl-2 and regulate the release of mi-
tochondrial proteins including Smac and cytochrome C. Taken to-
gether, a mechanism of action of survivin protein for the prevention 
of Smac and cytochrome C release can be explained by its direct 
effect on CREB in keeping the level of Bcl-2 high or by regulating 
the specific protein kinases that activate CREB.
According to previous studies, the transcriptional activity of CREB 
requires phosphorylation of serine 133 which provides positive con-
ditions for binding with CRE.17) Also, CREB must form a complex such 
as its binding with transducers of regulated CREB protein 2 (TORC2) 
to achieve its transcriptional activity. The increase of protein kinase 
A (PKA) and protein kinase G (PKG)-Iα activity induces the translo-
cation of TORC2 into the nucleus and also phosphorylates CREB.18) 
However, these intracellular protein kinases did not result in any 
change in the treatment of TAT-survivin (data not shown). We ob-
served in this study that TAT-survivin transduction significantly at-
tenuated the phosphorylation of p38 MAP kinase with doxorubicin 
treatment. We hypothesized that TAT-survivin could recover the 
CREB activation and Bcl-2 expression by suppressing p38, al-
though our data did not provide direct evidence for a role of p38 in 
this event. MAP kinases are known to regulate gene expression, and 
cell mitosis, differentiation, survival, and apoptosis in response to a 
wide variety of stimuli.19) Generally, activation of extracellular sig-
nal-regulated kinases is involved in cardiac cell proliferation and 
survival.20) On the other hand, Jun N-terminal kinases (JNKs) are 
activated by several stimuli that induce cardiac myocyte death.21) 
Recent evidence has implicated the dual role of p38 as a regulator 
of cell growth, and thus it can promote either cellular survival or 
death.2) Many reports have suggested that p38 activation is neces-
sary for cell death in response to various stimuli.22)23) In the oppo-
site case, other observations have indicated that p38 plays a role 
in cell protection against several stresses.24)25) We observed that 
there was a significant increase in the phosphorylation of JNK in 
doxorubicin-treated cardiac cells; however, no detectable difference 
was observed in JNK phosphorylation upon TAT-survivin treatment 
(data not shown). 
Several studies have shown that p38 MAP kinase can act a nega-
tive regulator of cardiac cell death against a number of stimuli.2)28)29) 
For example, p38 activation is associated with protection against 
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cardiac cell death in a myocardial infarction model by coronary ar-
tery ligation of rats.26) Similarly, p38 activation protects cardiac cells 
from thermal stress-induced cell death in an isolated perfused heart 
model.27) Moreover, the p38 MAP kinase pathway is substantially 
involved in the protective effect against doxorubicin-induced car-
diac cell death.2) Our results agree with these studies in that doxo-
rubicin-induced p38 phosphorylation was inhibited by TAT-survivin 
transduction, leading to protection from cardiac cell death. These 
results were accompanied by the nuclear translocation of CREB se-
questered in the cytoplasm, which results in the restoration of Bcl-2 
expression. A previous study has also reported that activation of p38 
MAP kinase in apoptotic cells correlates with reduced expression 
of Bcl-2 and survivin.28) 
Thus, we propose that a possible mechanism underlying the pro-
tective effect of TAT-survivin is that doxorubicin-induced p38 acti-
vation may suppress other intracellular factors which activate the 
nuclear translocation of CREB and transcriptional activity of Bcl-2. A 
study has revealed that p38 MAP kinase is shown to crosstalk in the 
PKA pathway which is an upstream positive regulator of CREB.29) 
Our results support the hypothesis that doxorubicin-induced p38 
activation can suppress the PKA pathway, leading to the inactivation 
of CREB and downregulation of Bcl-2 in H9c2 cardiac myocytes, and 
this event may be prevented by TAT-survivin protein transduction. 
Evidence has been reported that p38 MAP kinase mediates apoptotic 
cell death through downregulation of the Bcl family.30) The schemat-
ic diagram represents a model of the intracellular mechanism of the 
protective effect of survivin in doxorubicin-induced cell death (Fig. 
5). Promising further studies may prove our hypothesis and reveal 
the biological role of survivin in cardiac cells.
In conclusion, our findings suggest the direct transduction of 
survivin protein into cardiac myocytes using the PTD system can 
prevent cell death due to doxorubicin. We can assume that the pro-
tective role of survivin protein is closely associated with the regul-
ation of CREB activation and Bcl-2 expression, although its mecha-
PTD-survivin
Survival 
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PTD-survivin
Doxorubicin
Doxorubicin Other proteinsp38
Survivin expression
Bcl-2 expression
Smac Cytochrome C
Apoptosis
Nucleus
Caspase activity ↑
Cell membrane
Survivin
Bcl-2
Fig. 5. Schematic representation regarding the protective effect of survivin in doxorubicin-induced cardiac cell death. This figure is derived from our ex-
perimental findings and other previously reported studies. Pro-apoptotic signaling cascades induced by doxorubicin are shown as solid lines. Dotted lines 
represent pathways that are pro-survival or carry an anti-apoptotic signal. Protective proteins including survivin are illustrated by the gray boxes. PTD: 
protein transduction domain.
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nisms are not fully elucidated.
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